Novel Inhibitors of the Histone-Methyltransferase DOT1L Show Potent Antileukemic Activity in Patient-derived Xenografts (ChIP-seq dataset)

using ChIP-seq we examined Chromatin occupancy of the MLL-fusion complex members Menin and DOT1L after treatment with DOT1L methyltransferase inhibitors EPZ5676 and the novel compounds "compound 10" and "compound 11" as well as with the Menin-inhibitor VTP50469 in MOLM13 cells. Furthermore we used ChiP-seq to quantify the loss of H3K79me2 (histone mark deposited by DOT1L) after treatment with the DOT1L inhibitors EPZ5676 and "compound 10" in MOLM13 and RS4,11 cells. Overall design: Menin and DOT1L occupancy after treatment with DOT1L inhibitors and a Menin-inhibitor was assessed 4d after treatment with the drugs in MOLM13 cells via ChIP sequencing. Deposition of the histone mark H3K79me2 was measured at days 3, 6 and 9 after DOT1L-inhibitor treatment in MOLM13 and RS4,11 cells. For the analysis and normalization of the H3K79me2 ChIPseq we used drosophila spike-in (dm6 spike-in).